These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 20739347)

  • 21. Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease.
    Catani M; Mecocci P; Tarducci R; Howard R; Pelliccioli GP; Mariani E; Metastasio A; Benedetti C; Senin U; Cherubini A
    J Am Geriatr Soc; 2002 Oct; 50(10):1707-10. PubMed ID: 12366626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study.
    Nilsen LH; Melø TM; Saether O; Witter MP; Sonnewald U
    J Neurochem; 2012 Nov; 123(4):532-41. PubMed ID: 22943908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease.
    Bartha R; Smith M; Rupsingh R; Rylett J; Wells JL; Borrie MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):786-93. PubMed ID: 18252268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging.
    Parnetti L; Tarducci R; Presciutti O; Lowenthal DT; Pippi M; Palumbo B; Gobbi G; Pelliccioli GP; Senin U
    Mech Ageing Dev; 1997 Jul; 97(1):9-14. PubMed ID: 9223122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early increases in brain myo-inositol measured by proton magnetic resonance spectroscopy in term infants with neonatal encephalopathy.
    Robertson NJ; Lewis RH; Cowan FM; Allsop JM; Counsell SJ; Edwards AD; Cox IJ
    Pediatr Res; 2001 Dec; 50(6):692-700. PubMed ID: 11726726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis.
    Fernando KT; McLean MA; Chard DT; MacManus DG; Dalton CM; Miszkiel KA; Gordon RM; Plant GT; Thompson AJ; Miller DH
    Brain; 2004 Jun; 127(Pt 6):1361-9. PubMed ID: 15128615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease.
    Mlynárik V; Cacquevel M; Sun-Reimer L; Janssens S; Cudalbu C; Lei H; Schneider BL; Aebischer P; Gruetter R
    J Alzheimers Dis; 2012; 31 Suppl 3():S87-99. PubMed ID: 22451319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reproducibility of short echo time proton magnetic resonance spectroscopy using point-resolved spatially localized spectroscopy sequence in normal human brains.
    Hoshino Y; Yoshikawa K; Inoue Y; Asai S; Nakamura T; Ogino T; Umeda M; Iwamoto A
    Radiat Med; 1999; 17(2):115-20. PubMed ID: 10399778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spectroscopic meta-analyses reveal novel metabolite profiles across methamphetamine and cocaine substance use disorder.
    Smucny J; Maddock RJ
    Drug Alcohol Depend; 2023 Jul; 248():109900. PubMed ID: 37148676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuronal and Glial Metabolite Abnormalities in Participants With Persistent Neuropsychiatric Symptoms After COVID-19: A Brain Proton Magnetic Resonance Spectroscopy Study.
    Ernst T; Ryan MC; Liang HJ; Wang JP; Cunningham E; Saleh MG; Kottilil S; Chang L
    J Infect Dis; 2023 Nov; 228(11):1559-1570. PubMed ID: 37540098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of short echo time two-dimensional 1H-magnetic resonance spectroscopy in temporal lobe epilepsy with negative magnetic resonance imaging findings.
    Shen J; Zhang L; Tian X; Liu J; Ge X; Zhang X
    J Int Med Res; 2009; 37(4):1211-9. PubMed ID: 19761706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder.
    Davanzo P; Thomas MA; Yue K; Oshiro T; Belin T; Strober M; McCracken J
    Neuropsychopharmacology; 2001 Apr; 24(4):359-69. PubMed ID: 11182531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
    Waldman AD; Rai GS
    Neuroradiology; 2003 Aug; 45(8):507-12. PubMed ID: 12879326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers.
    Sturrock A; Laule C; Wyper K; Milner RA; Decolongon J; Dar Santos R; Coleman AJ; Carter K; Creighton S; Bechtel N; Bohlen S; Reilmann R; Johnson HJ; Hayden MR; Tabrizi SJ; Mackay AL; Leavitt BR
    Mov Disord; 2015 Mar; 30(3):393-401. PubMed ID: 25690257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
    Huang W; Alexander GE; Chang L; Shetty HU; Krasuski JS; Rapoport SI; Schapiro MB
    Neurology; 2001 Aug; 57(4):626-32. PubMed ID: 11524470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments.
    John NA; Solanky BS; De Angelis F; Parker RA; Weir CJ; Stutters J; Carrasco FP; Schneider T; Doshi A; Calvi A; Williams T; Plantone D; Monteverdi A; MacManus D; Marshall I; Barkhof F; Gandini Wheeler-Kingshott CAM; Chataway J;
    J Magn Reson Imaging; 2024 Jun; 59(6):2192-2201. PubMed ID: 37787109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proton magnetic resonance spectroscopy in dementia of Alzheimer type.
    Heun R; Schlegel S; Graf-Morgenstern M; Tintera J; Gawehn J; Stoeter P
    Int J Geriatr Psychiatry; 1997 Mar; 12(3):349-58. PubMed ID: 9152720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
    Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
    Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinctive Neurochemistry in Alzheimer's Disease via 7 T In Vivo Magnetic Resonance Spectroscopy.
    Marjańska M; McCarten JR; Hodges JS; Hemmy LS; Terpstra M
    J Alzheimers Dis; 2019; 68(2):559-569. PubMed ID: 30775983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alzheimer disease: absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy.
    Stoppe G; Bruhn H; Pouwels PJ; Hänicke W; Frahm J
    Alzheimer Dis Assoc Disord; 2000; 14(2):112-9. PubMed ID: 10850750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.